Incyte Cash Flows Other Operating vs Cash And Cash Equivalents Changes Analysis
INCY Stock | USD 53.06 0.44 0.82% |
Incyte financial indicator trend analysis is infinitely more than just investigating Incyte recent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Incyte is a good investment. Please check the relationship between Incyte Cash Flows Other Operating and its Cash And Cash Equivalents Changes accounts. Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Incyte. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in main economic indicators. For more information on how to buy Incyte Stock please use our How to Invest in Incyte guide.
Cash Flows Other Operating vs Cash And Cash Equivalents Changes
Cash Flows Other Operating vs Cash And Cash Equivalents Changes Correlation Analysis
The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Incyte Cash Flows Other Operating account and Cash And Cash Equivalents Changes. At this time, the significance of the direction appears to have fragmental relationship.
The correlation between Incyte's Cash Flows Other Operating and Cash And Cash Equivalents Changes is 0.44. Overlapping area represents the amount of variation of Cash Flows Other Operating that can explain the historical movement of Cash And Cash Equivalents Changes in the same time period over historical financial statements of Incyte, assuming nothing else is changed. The correlation between historical values of Incyte's Cash Flows Other Operating and Cash And Cash Equivalents Changes is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Cash Flows Other Operating of Incyte are associated (or correlated) with its Cash And Cash Equivalents Changes. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Cash And Cash Equivalents Changes has no effect on the direction of Cash Flows Other Operating i.e., Incyte's Cash Flows Other Operating and Cash And Cash Equivalents Changes go up and down completely randomly.
Correlation Coefficient | 0.44 |
Relationship Direction | Positive |
Relationship Strength | Weak |
Cash Flows Other Operating
Cash And Cash Equivalents Changes
Most indicators from Incyte's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Incyte current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Incyte. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in main economic indicators. For more information on how to buy Incyte Stock please use our How to Invest in Incyte guide.At this time, Incyte's Selling General Administrative is fairly stable compared to the past year. Tax Provision is likely to rise to about 229.8 M in 2024, whereas Sales General And Administrative To Revenue is likely to drop 0.30 in 2024.
2021 | 2022 | 2023 | 2024 (projected) | Total Operating Expenses | 2.2B | 2.6B | 2.8B | 2.9B | Cost Of Revenue | 151.0M | 207.0M | 255M | 267.8M |
Incyte fundamental ratios Correlations
Click cells to compare fundamentals
Incyte Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Incyte fundamental ratios Accounts
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Total Assets | 3.4B | 3.6B | 4.9B | 5.8B | 6.8B | 7.1B | |
Short Long Term Debt Total | 50.9M | 34.9M | 34.3M | 44.6M | 38.3M | 36.4M | |
Other Current Liab | 76.1M | 86.2M | 82.8M | 469.7M | 111.7M | 70.6M | |
Total Current Liabilities | 500.5M | 648.8M | 885.1M | 1.2B | 1.2B | 1.3B | |
Total Stockholder Equity | 2.6B | 2.6B | 3.8B | 4.4B | 5.2B | 5.4B | |
Property Plant And Equipment Net | 406.6M | 588.1M | 751.5M | 765.6M | 777.0M | 815.9M | |
Net Debt | (1.8B) | (1.5B) | (2.0B) | (2.9B) | (3.2B) | (3.0B) | |
Retained Earnings | (1.4B) | (1.7B) | (777.9M) | (437.2M) | 160.4M | 168.4M | |
Accounts Payable | 83.6M | 98.8M | 172.1M | 277.5M | 109.6M | 115.1M | |
Cash | 1.8B | 1.5B | 2.1B | 3.0B | 3.2B | 3.4B | |
Non Current Assets Total | 889.7M | 1.1B | 1.7B | 1.6B | 2.1B | 2.2B | |
Cash And Short Term Investments | 2.1B | 1.8B | 2.3B | 3.2B | 3.7B | 3.8B | |
Common Stock Shares Outstanding | 217.7M | 218.1M | 222.1M | 224.0M | 225.9M | 130.7M | |
Liabilities And Stockholders Equity | 3.4B | 3.6B | 4.9B | 5.8B | 6.8B | 7.1B | |
Non Current Liabilities Total | 327.9M | 300.9M | 278.3M | 254.3M | 351.9M | 340.4M | |
Other Current Assets | 94.2M | 103.3M | 165.3M | 167.0M | 182.8M | 192.0M | |
Other Stockholder Equity | 4.0B | 4.4B | 4.6B | 4.8B | 5.0B | 5.3B | |
Total Liab | 828.3M | 949.7M | 1.2B | 1.5B | 1.6B | 1.7B | |
Total Current Assets | 2.5B | 2.4B | 3.2B | 4.2B | 4.6B | 4.9B | |
Short Term Debt | 28.3M | 15.0M | 13.2M | 11.4M | 9.1M | 8.7M | |
Non Currrent Assets Other | 55.6M | 62.8M | 68.1M | 106.1M | 260.9M | 274.0M | |
Net Receivables | 308.8M | 482.0M | 616.3M | 644.9M | 743.6M | 780.7M | |
Property Plant And Equipment Gross | 406.6M | 559.6M | 751.5M | 765.6M | 1.0B | 1.1B | |
Accumulated Other Comprehensive Income | (15.5M) | (15.4M) | (19.5M) | 15.1M | 13.1M | 13.8M | |
Intangible Assets | 193.8M | 172.3M | 150.8M | 129.2M | 123.5M | 74.2M | |
Short Term Investments | 284.9M | 288.4M | 290.8M | 287.5M | 442.7M | 464.8M | |
Other Assets | 55.6M | 25.1M | 467.5M | 564.0M | 648.6M | 681.1M | |
Common Stock Total Equity | 216K | 219K | 221K | 223K | 256.5K | 154K | |
Common Stock | 216K | 219K | 221K | 223K | 224K | 157.9K | |
Property Plant Equipment | 377.6M | 559.6M | 723.9M | 739.3M | 850.2M | 892.7M | |
Current Deferred Revenue | 312.4M | 448.9M | 617.0M | 457.9M | 1.0B | 1.1B | |
Other Liab | 271.2M | 266M | 244M | 269.6M | 310.0M | 156.9M | |
Inventory | 16.5M | 36.0M | 56.9M | 121.0M | 63.0M | 66.1M | |
Net Tangible Assets | 2.2B | 2.3B | 3.5B | 4.1B | 4.7B | 4.9B | |
Retained Earnings Total Equity | (1.4B) | (1.7B) | (777.9M) | (437.2M) | (502.8M) | (527.9M) | |
Capital Surpluse | 4.0B | 4.4B | 4.6B | 4.8B | 5.5B | 3.4B | |
Non Current Liabilities Other | 315.0M | 318.5M | 309.0M | 313.8M | 322.7M | 278.6M |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Incyte. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in main economic indicators. For more information on how to buy Incyte Stock please use our How to Invest in Incyte guide.Note that the Incyte information on this page should be used as a complementary analysis to other Incyte's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Idea Analyzer module to analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas.
Complementary Tools for Incyte Stock analysis
When running Incyte's price analysis, check to measure Incyte's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Incyte is operating at the current time. Most of Incyte's value examination focuses on studying past and present price action to predict the probability of Incyte's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Incyte's price. Additionally, you may evaluate how the addition of Incyte to your portfolios can decrease your overall portfolio volatility.
Risk-Return Analysis View associations between returns expected from investment and the risk you assume | |
Funds Screener Find actively-traded funds from around the world traded on over 30 global exchanges | |
Sectors List of equity sectors categorizing publicly traded companies based on their primary business activities | |
Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital | |
Content Syndication Quickly integrate customizable finance content to your own investment portal | |
ETFs Find actively traded Exchange Traded Funds (ETF) from around the world | |
Portfolio Analyzer Portfolio analysis module that provides access to portfolio diagnostics and optimization engine | |
Share Portfolio Track or share privately all of your investments from the convenience of any device | |
Idea Breakdown Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes | |
Watchlist Optimization Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm | |
Money Managers Screen money managers from public funds and ETFs managed around the world |
Is Incyte's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Incyte. If investors know Incyte will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Incyte listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 6.705 | Earnings Share 3.3 | Revenue Per Share 16.82 | Quarterly Revenue Growth 0.089 | Return On Assets 0.0689 |
The market value of Incyte is measured differently than its book value, which is the value of Incyte that is recorded on the company's balance sheet. Investors also form their own opinion of Incyte's value that differs from its market value or its book value, called intrinsic value, which is Incyte's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Incyte's market value can be influenced by many factors that don't directly affect Incyte's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Incyte's value and its price as these two are different measures arrived at by different means. Investors typically determine if Incyte is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Incyte's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.